Quimpharma has completed the divestiture of a product portfolio to Megalabs
Quimpharma has completed the divestiture of a product portfolio to Megalabs México.
Quimpharma is a Mexican pharmaceutical company focused on the development, manufacture and distribution of prescription, over-the-counter (OTC), food supplement and dermocosmetic products. With over 22 years of history, the company has established a strong position in the Mexican market, supported by a robust R&D division and a portfolio of more than 40 products across key therapeutic categories. The company operates a manufacturing facility with liquid and solid production lines, a distribution center and corporate offices in Mexico City, enabling nationwide reach and consistent product availability.
Megalabs México, through Italmex, is part of Megalabs, a Uruguay-based pharmaceutical group with a strong presence across Latin America. The company develops and commercializes innovative, high-quality pharmaceutical products, dermocosmetics and nutritional supplements across multiple therapeutic areas, working closely with healthcare professionals to support patients’ health and wellbeing throughout Mexico and the region.
Oaklins’ team in Mexico acted as the exclusive sell-side advisor to Quimpharma in the divestiture of a product portfolio to Megalabs. This transaction highlights Oaklins’ expertise in the healthcare sector and reinforces its strong track record advising mid-market companies through complex, cross-border processes.
Contacter l'équipe de la transaction
Transactions connexes
UKAT Group has acquired Bayberry Limited
UK Addiction Treatment (UKAT) Group, a leading UK provider of residential addiction, mental health and behavioral health treatment backed by Sullivan Street Partners, has acquired Bayberry Limited, a specialist mental health and wellbeing treatment provider. Joining UKAT enables Bayberry to preserve continuity of care for patients and referral partners, retain the strength of its clinical team and benefit from UKAT’s operational infrastructure, referral network and marketing channels. This partnership supports Bayberry’s next stage of development while preserving the qualities that differentiate its service offering.
En apprendre plusMedicija has acquired Saulės Šeimos Medicinos Centras
Medicija has acquired a 100% stake in Saulės Šeimos Medicinos Centras.
En apprendre plusIXICO has completed a fundraising
IXICO plc, a specialist in AI-driven neuroimaging analytics, has completed a US$13.5 million gross capital raise. The funds will be used to support the company’s tech bio strategy, which will see IXICO partner its platform to maximize its potential.
En apprendre plus